Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Rugo, HS"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 29
Tytuł:
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
Autorzy:
Palli SR
Grabner M
Quimbo RA
Rugo HS
Pokaż więcej
Temat:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło:
Cancer Management and Research, Vol 2015, Iss default, Pp 175-188 (2015)
Opis pliku:
electronic resource
Relacje:
http://www.dovepress.com/the-impact-of-5-hydroxytryptamine-receptor-antagonists-on-chemotherapy-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322
Dostęp URL:
https://doaj.org/article/5dcab0d57c8a4cdd87063ddf4520650c  Link otwiera się w nowym oknie
Czasopismo naukowe
Szczegóły
Tytuł:
Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report
Autorzy:
Linker, CA
Ries, CA
Damon, LE
Rugo, HS
Wolf, JL
Pokaż więcej
Źródło:
Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation. 22(9):865-872
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice.
Autorzy:
Brufsky A; UPMC Hillman Cancer Center, Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Liu X; Pfizer Inc., New York, NY 10001, USA.
Li B; Pfizer Inc., New York, NY 10001, USA.
McRoy L; Pfizer Inc., New York, NY 10001, USA.
Chen C; Pfizer Inc., New York, NY 10001, USA.
Layman RM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rugo HS; Department of Medicine (Hematology/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Nov 02; Vol. 15 (21). Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.
Autorzy:
Fillbrunn M; Analysis Group, Inc., Boston, Massachusetts, USA.
Signorovitch J; Analysis Group, Inc., Boston, Massachusetts, USA. .
André F; Institut Gustave Roussy, Villejuif, France.
Wang I; Novartis, East Hanover, New Jersey, USA.
Lorenzo I; Novartis, Madrid, Spain.
Ridolfi A; Novartis, Paris, France.
Park J; Novartis, East Hanover, New Jersey, USA.
Dua A; Analysis Group, Inc., Boston, Massachusetts, USA.
Rugo HS; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Sep 21; Vol. 22 (1), pp. 1002. Date of Electronic Publication: 2022 Sep 21.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Breast Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Class I Phosphatidylinositol 3-Kinases/genetics ; Disease-Free Survival ; Female ; Humans ; Mutation ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositols/therapeutic use ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer.
Autorzy:
Apple AC; University of California San Francisco, Department of Neurology, Memory and Aging Center, San Francisco, CA, USA.
Lindbergh CA; University of California San Francisco, Department of Neurology, Memory and Aging Center, San Francisco, CA, USA.; Department of Psychiatry, Connecticut School of Medicine, USA.
Landau SM; School of Public Health and Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.; Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
DeLuca A; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Eberling JL; PhD Michael J. Fox Foundation New York, NY, USA.
Jagust WJ; School of Public Health and Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.; Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Kramer JH; University of California San Francisco, Department of Neurology, Memory and Aging Center, San Francisco, CA, USA.
Rugo HS; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Heflin LH; New Mexico Highlands University, Department of Psychology, Las Vegas, NM, USA.
Pokaż więcej
Źródło:
Journal of oncology [J Oncol] 2022 Apr 16; Vol. 2022, pp. 5899728. Date of Electronic Publication: 2022 Apr 16 (Print Publication: 2022).
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
Autorzy:
Elghazaly H; Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Rugo HS; Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94158, USA.
Azim HA; Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Giza 12613, Egypt.
Swain SM; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, Washington, DC 20007, USA.
Arun B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Aapro M; Breast Center, Clinique de Genolier, 1272 Genolier, Switzerland.
Perez EA; Department of Hematology & Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.
Anderson BO; Breast Health Global Initiative, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98195, USA.
Penault-Llorca F; Department of Pathology, Clermont Auvergne University, INSERM U1240 'Molecular Imaging and Theranostic Strategies', Center Jean Perrin, Montalembert, 63000 Clermont-Ferrand, France.
Conte P; Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IOV IRCCS, 35128 Padova, Italy.
El Saghir NS; Department of Internal Medicine, Division of Hematology Oncology, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon.
Yip CH; Subang Jaya Medical Centre, Kuala Lumpur 47500, Malaysia.
Ghosn M; Hematology and Oncology Department, Saint Joseph University, Beirut 1104 2020, Lebanon.
Poortmans P; Iridium Kankernetwerk and Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk-Antwerp, Belgium.
Shehata MA; Clinical oncology Department, Menoufia University, Shebin Elkom 51132, Egypt.
Giuliano AE; Department of Surgery, Surgical Oncology Division, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Leung JWT; Department of Breast Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IOV IRCCS, 35128 Padova, Italy.
Gligorov J; Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, INSERM U938, 75013 Paris, France.
Gulluoglu BM; Breast & Endocrine Surgery Unit, Marmara University School of Medicine, University Hospital, Istanbul 34722, Turkey.
Abdel Aziz H; Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Frolova M; Federal State Budgetary Institution 'NN Blokhin National Medical Research Center of Oncology' of the Ministry of Health of the Russian Federation, 127994 Moscow, Russia.
Sabry M; Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Balch CM; Surgical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Orecchia R; Scientific Directorate, IRCCS European Institute of Oncology (IEO), and University of Milan, 20122 Milan, Italy.
El-Zawahry HM; Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Giza 12613, Egypt.
Al-Sukhun S; Al Hyatt Oncology Practice, Amman 11183, Jordan.
Abdel Karim K; Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Kandil A; Department of Clinical Oncology, Alexandria School of Medicine, Alexandria 21131, Egypt.
Paltuev RM; Russian Association of Oncological Mammology, Department of Breast Tumours of Federal State Budgetary Institution 'Petrov Research Institute of Oncology', 197758 Saint Petersburg, Russia.
Foheidi M; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah 22384, Saudi Arabia.
El-Shinawi M; Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.; Vice President of Galala University, Galala University, Suez 435611, Egypt.
ElMahdy M; Department of Pathology, Ain shams University, Cairo 11566, Egypt.
Abulkhair O; Oncology Department, Alfaisal university, Alhabib Hospital, Riyad 11533, Saudi Arabia.
Yang W; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Aref AT; The School of Public Health, University of Adelaide, Adelaide 5005, Australia.
Bakkach J; Biomedical Genomics & Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, Abdel Malek Essaadi University, Tangier 90000, Morocco.
Bahie Eldin N; Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Elghazawy H; Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 May 08; Vol. 13 (9). Date of Electronic Publication: 2021 May 08.
Typ publikacji:
Guideline
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Using diagnosis codes in claims data to identify cohorts of breast cancer patients following initial treatment.
Autorzy:
Franc BL; Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Stanford University School of Medicine, Stanford, CA, USA.
Thombley R; Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Stanford University School of Medicine, Stanford, CA, USA.
Luo Y; Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, USA.
John Boscardin W; Department of Medicine, Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Rugo HS; Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Seidenwurm D; Sutter Medical Foundation, Sacramento, CA, USA.
Dudley RA; Philip R. Lee Institute for Health Policy Studies, Center for Healthcare Value, University of California, San Francisco, CA, USA.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2020 Jul; Vol. 26 (7), pp. 1472-1474. Date of Electronic Publication: 2020 Jan 20.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Breast Neoplasms*/epidemiology
Breast Neoplasms*/therapy
Algorithms ; Female ; Humans ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identifying tests related to breast cancer care in claims data.
Autorzy:
Franc BL; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Thombley R; Philip R. Lee Institute for Health Policy Studies, Center for Healthcare Value, University of California, San Francisco, CA, USA.
Luo Y; Philip R. Lee Institute for Health Policy Studies, Center for Healthcare Value, University of California, San Francisco, CA, USA.
Boscardin WJ; Department of Medicine, Epidemiology & Biostatistics, San Francisco, CA, USA.
Rugo HS; Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Seidenwurm D; Sutter Medical Foundation, Sacramento, CA, USA.
Dudley RA; Philip R. Lee Institute for Health Policy Studies, Center for Healthcare Value, University of California, San Francisco, CA, USA.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2020 Jun; Vol. 26 (6), pp. 1227-1230. Date of Electronic Publication: 2019 Nov 18.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Breast Neoplasms*/epidemiology
Breast Neoplasms*/therapy
Aged ; Cohort Studies ; Female ; Humans ; Medicare ; Neoplasm Recurrence, Local ; SEER Program ; United States/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Autorzy:
Gelmon KA; BC Cancer, Vancouver, BC, Canada.
Cristofanilli M; Feinberg School of Medicine, Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL, USA.
Rugo HS; Diller Family Comprehensive Cancer Center, University of California San Francisco Helen, San Francisco, CA, USA.
DeMichele AM; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Joy AA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Castrellon A; Breast Cancer Center, Memorial Healthcare System, Hollywood, FL, USA.
Sleckman B; Mercy Hospital St. Louis, St. Louis, MO, USA.
Mori A; Pfizer Oncology, Milan, Italy.
Theall KP; Pfizer Oncology, Cambridge, MA, USA.
Lu DR; Pfizer Inc, La Jolla, CA, USA.
Huang X; Pfizer Oncology, New York, NY, USA.
Bananis E; Pfizer Oncology, New York, NY, USA.
Finn RS; David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA, USA.
Slamon DJ; David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA, USA.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2020 Mar; Vol. 26 (3), pp. 368-375. Date of Electronic Publication: 2019 Aug 25.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Fulvestrant ; Humans ; North America ; Piperazines ; Pyridines ; Receptor, ErbB-2 ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
Autorzy:
Schwartzberg L; West Cancer Center, Memphis, Tennessee.
Karthaus M; Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany.
Rossi G; Helsinn Healthcare SA, Lugano, Switzerland.
Rizzi G; Helsinn Healthcare SA, Lugano, Switzerland.
Borroni ME; Helsinn Healthcare SA, Lugano, Switzerland.
Rugo HS; University of California San Francisco Comprehensive Cancer Center, San Francisco, California.
Jordan K; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Germany.
Hansen V; Northern Utah Associates, Ogden, Utah.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2019 May; Vol. 8 (5), pp. 2064-2073. Date of Electronic Publication: 2019 Apr 09.
Typ publikacji:
Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiemetics/*administration & dosage
Aprepitant/*administration & dosage
Dexamethasone/*administration & dosage
Drug-Related Side Effects and Adverse Reactions/*prevention & control
Isoquinolines/*administration & dosage
Palonosetron/*administration & dosage
Pyridines/*administration & dosage
Quinuclidines/*administration & dosage
Administration, Oral ; Anthracyclines/adverse effects ; Antiemetics/therapeutic use ; Aprepitant/therapeutic use ; Cyclophosphamide/adverse effects ; Dexamethasone/therapeutic use ; Double-Blind Method ; Drug Combinations ; Female ; Humans ; Isoquinolines/therapeutic use ; Male ; Middle Aged ; Palonosetron/therapeutic use ; Pyridines/therapeutic use ; Quinuclidines/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.
Autorzy:
Peterson DE; School of Dental Medicine and Neag Comprehensive Cancer Center, UConn Health, Farmington, Connecticut.
O'Shaughnessy JA; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas.
Rugo HS; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Elad S; Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, New York.; Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York.
Schubert MM; School of Dentistry, University of Washington and Seattle Cancer Care Alliance, Seattle, Washington.
Viet CT; New York University College of Dentistry, New York, New York.
Campbell-Baird C; Penn State Hershey Medical Center, Hershey, Pennsylvania.
Hronek J; Tennessee Oncology/Sarah Cannon Research Institute, Nashville, Tennessee.
Seery V; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Divers J; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas.
Glaspy J; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California.
Schmidt BL; New York University College of Dentistry, New York, New York.
Meiller TF; School of Dentistry and the Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2016 Aug; Vol. 5 (8), pp. 1897-907. Date of Electronic Publication: 2016 Jun 23.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents/*adverse effects
Stomatitis/*chemically induced
TOR Serine-Threonine Kinases/*antagonists & inhibitors
Breast Neoplasms/drug therapy ; Female ; Humans ; Incidence ; Pain/chemically induced ; Stomatitis/epidemiology ; Stomatitis/pathology ; Stomatitis/therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.
Autorzy:
Cortés J; Ramon y Cajal University Hospital, Madrid, Spain ; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron 119-129, Barcelona, Spain.
Rugo HS; University of California, San Francisco, CA USA.
Twelves C; St. James's University Hospital, University of Leeds, Leeds, UK.
Awada A; Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium.
Perez EA; Mayo Clinic, Jacksonville, FL USA.
Im SA; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Zhao C; Nektar Therapeutics, San Francisco, CA USA.
Hoch U; Nektar Therapeutics, San Francisco, CA USA.
Tomkinson D; Nektar Therapeutics, San Francisco, CA USA.
Buchanan J; Nektar Therapeutics, San Francisco, CA USA.
Tagliaferri M; Nektar Therapeutics, San Francisco, CA USA.
Hannah A; Consultant, Sebastopol, CA USA.
O'Shaughnessy J; Baylor-Sammons Cancer Center, Texas Oncology, U.S. Oncology, Dallas, TX USA.
Pokaż więcej
Źródło:
SpringerPlus [Springerplus] 2016 Jul 08; Vol. 5 (1), pp. 1033. Date of Electronic Publication: 2016 Jul 08 (Print Publication: 2016).
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay.
Autorzy:
Magbanua MJ; Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA, 94115, United States of America.
Pugia M; Siemens Healthcare Diagnostics, Elkhart, IN, 46516, United States of America.
Lee JS; Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA, 94115, United States of America.
Jabon M; Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA, 94115, United States of America.
Wang V; Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA, 94115, United States of America.
Gubens M; Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA, 94115, United States of America.
Marfurt K; Siemens Healthcare Diagnostics, Elkhart, IN, 46516, United States of America.
Pence J; Siemens Healthcare Diagnostics, Elkhart, IN, 46516, United States of America.
Sidhu H; Siemens Healthcare Diagnostics, Elkhart, IN, 46516, United States of America.
Uzgiris A; Siemens Healthcare Diagnostics, Elkhart, IN, 46516, United States of America.
Rugo HS; Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA, 94115, United States of America.
Park JW; Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA, 94115, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Oct 23; Vol. 10 (10), pp. e0141166. Date of Electronic Publication: 2015 Oct 23 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Biomarkers, Tumor/*genetics
Breast Neoplasms/*pathology
Lung Neoplasms/*pathology
Neoplasm Proteins/*genetics
Neoplastic Cells, Circulating/*pathology
Biomarkers, Tumor/metabolism ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Case-Control Studies ; Cell Count/instrumentation ; Cell Count/methods ; Endothelial Cells/metabolism ; Endothelial Cells/pathology ; Female ; Filtration ; Gene Expression ; Humans ; Immunoassay/methods ; Lung Neoplasms/diagnosis ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Male ; Mesenchymal Stem Cells/metabolism ; Mesenchymal Stem Cells/pathology ; Microfluidic Analytical Techniques/instrumentation ; Neoplasm Metastasis ; Neoplasm Proteins/metabolism ; Neoplastic Cells, Circulating/metabolism ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Reproducibility of Results
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 29

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies